SunTrust Robinson Reiterates a Buy Rating on Adaptimmune Therapeutics

By Jason Carr

SunTrust Robinson analyst Peter Lawson reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP) on October 9 and set a price target of $10. The company’s shares opened today at $7.88.

According to, Lawson is a 5-star analyst with an average return of 18.8% and a 55.0% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Bellicum Pharmaceuticals, and Crispr Therapeutics AG.

Adaptimmune Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.

The company has a one-year high of $9.29 and a one-year low of $3.76. Currently, Adaptimmune Therapeutics has an average volume of 336.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adaptimmune Therapeutics Plc is a clinical stage biopharmaceutical company, which focuses on novel cancer immunotherapy products based on T-cell receptor platform. Its TCR platform targets NY-ESO-1 cancer antigen. The company was founded in December 2014 and is headquartered in Oxford, the United Kingdom.